Continuous glucose monitoring after islet transplantation in type 1 diabetes: An excellent graft function (β-score greater than 7) is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (-βscore greater than 3)

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 11, 2012, Pages

  Vantyghem, Marie Christine ^a,b   Raverdy, Violeta ^a,b   Balavoine, Anne Sophie ^a   Defrance, Frédérique ^a   Caiazzo, Robert ^a,b   Arnalsteen, Laurent ^a   Gmyr, Valéry ^a,b   Hazzan, Marc ^a   Noël, Christian ^a   Kerr Conte, Julie ^a,b   Pattou, Francois ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84868624334     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2115     Document Type: Article

References (22)

1. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B, Oberholzer J, Odorico JS, Garfinkel MR, Levy M, Pattou F, Berney T, Secchi A, Messinger S, Senior PA, Maffi P, Posselt A, Stock PG, Kaufman DB, Luo X, Kandeel F, Cagliero E, Turgeon NA, Witkowski P, Naji A, et al. 2012 Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35:1436-1445
2. Vantyghem MC, Press M 2006 Management strategies for brittle diabetes. Ann Endocrinol (Paris) 67:287-296
3. Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H 2011 Continuous glucose monitoring: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:2968-2979
4. Kessler L, Passemard R, Oberholzer J, Benhamou PY, Bucher P, Toso C, Meyer P, Penfornis A, Badet L, Wolf P, Colin C, Morel P, Pinget M; GRAGIL Group 2002 Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: interest of continuous glucose monitoring. Diabetes Care 25:2256-2262
5. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA 2006 Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther 8:165-173 (Pubitemid 43848039)
6. Gorn L, Faradji RN, Messinger S, Monroy K, Baidal DA, Froud T, Mastrototaro J, Ricordi C, Alejandro R 2008 Impact of islet transplantation on glycemic control as evidenced by a continuous glucose monitoring system. J Diabetes Sci Technol 2:221-228
7. Vantyghem MC, Kerr-Conte J, Arnalsteen L, Sergent G, Defrance F, Gmyr V, Declerck N, Raverdy V, Vandewalle B, Pigny P, Noel C, Pattou F 2009 Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 32:1473-1478
8. Vantyghem MC, Marcelli-Tourvieille S, Fermon C, Duhamel A, Raverdy V, Arnalsteen L, Kerr-Conte J, Noel C, Fontaine P, Pattou F 2009 Intraperitoneal insulin infusion versus islet transplantation: comparative study in patients with type 1 diabetes. Transplantation 87:66-71
9. Ryan EA, Paty BW, Senior PA, Lakey JR, Bigam D, Shapiro AM 2005 Beta-score: an assessment of β-cell function after islet transplantation. Diabetes Care 28:343-347 (Pubitemid 40170937)
10. Kilpatrick ES, Rigby AS, Atkin SL 2008 Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51:365-371
11. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES 2010 The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 33:2310-2313
12. Sancho A, Pastor MC, Cañas L, Morales Indiano C, Ardèvol M, Aguerrevere S, Juega J, Romero R, Lauzurica R 2011 Posttransplantation anemia: relationship with inflammatory markers, oxidation, and prohepcidin levels. Transplant Proc 43:2196-2198
13. Hirsch D, Odorico J, Danobeitia JS, Alejandro R, Rickels MR, Hanson M, Radke N, Baidal D, Hullett D, Naji A, Ricordi C, Kaufman D, Fernandez L 2012 Early metabolic markers that anticipate loss of insulin independence in type 1 diabetic islet allograft recipients.AmJ Transplant 12:1275-1289
14. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W 2009 Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care 32:1188-1193
15. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Fox LA, Beck RW, Xing D 2010 Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. Diabetes Care 33:1297-1299
16. Rodríguez LM, Knight RJ, Heptulla RA 2010 Continuous glucose monitoring in subjects after simultaneous pancreas-kidney and kidney- alone transplantation. Diabetes Technol Ther 12:347-351
17. Derosa G, Salvadeo SA, Mereu R, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Tinelli C 2009 Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes Technol Ther 11:159-169
18. Thompson DM, Meloche M, Ao Z, Paty B, Keown P, Shapiro RJ, HoS, Worsley D, Fung M, Meneilly G, Begg I, Al Mehthel M, Kondi J, Harris C, Fensom B, Kozak SE, Tong SO, Trinh M, Warnock GL 2011 Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 91:373-378
19. Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B, White NH, Arbelaez AM, Beck RW, Kollman C, Ruedy K; Diabetes Research in Children Network (DirecNet) Study Group 2012 Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual β-cell function. Diabetes Care 35:817-820
20. Wang C, Lv L, Yang Y, Chen D, Liu G, Chen L, Song Y, He L, Li X, Tian H, Jia W, Ran X 2012 Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly-diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf) 76:810-815
21. Castaldo E, Sabato D, Lauro D, Sesti G, Marini MA 2011 Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One 6:e28312
22. Peña AS, Couper JJ, Harrington J, Gent R, Fairchild J, Tham E, Baghurst P 2012 Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. Diabetes Technol Ther 14:457-462